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While home dialysis is being promoted, there are few
comparative effectiveness studies of home-based modalities
to guide patient decisions. To address this, we matched 1116
daily home hemodialysis (DHD) patients by propensity scores
to 2784 contemporaneous USRDS patients receiving home
peritoneal dialysis (PD), and compared hospitalization rates
from cardiovascular, infectious, access-related or bleeding
causes (prespecified composite), and modality failure risk.
We performed similar analyses for 1187 DHD patients
matched to 3173 USRDS patients receiving in-center
conventional hemodialysis (CHD). The composite
hospitalization rate was significantly lower with DHD than
with PD (0.93 vs. 1.35/patient-year, hazard ratio=0.73 (95%
CI= 0.67–0.79)). DHD patients spent significantly fewer days
in hospital than PD patients (5.2 vs. 9.2 days/patient-year),
and significantly more DHD patients remained admission-free
(52% DHD vs. 32% PD). In contrast, there was no significant
difference in hospitalizations between DHD and CHD
(DHD vs. CHD: 0.93 vs. 1.10/patient-year, hazard ratio 0.92
(0.85–1.00)). Cardiovascular hospitalizations were lower with
DHD than with CHD (0.68 (0.61–0.77)), while infectious and
access hospitalizations were higher (1.15 (1.04–1.29) and
1.25 (1.08–1.43), respectively). Significantly more PD than
DHD patients switched back to in-center HD (44% vs. 15%;
3.4 (2.9–4.0)). In this prevalent cohort, home DHD was
associated with fewer admissions and hospital days than
PD, and a substantially lower risk of modality failure.
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Home-based dialysis modalities are being increasingly pro-
moted internationally as preferred renal replacement therapy
options when transplantation is not immediately feasible.1–6
Both home peritoneal dialysis (PD) and home hemodialysis
(HD) are associated with similar or better survival than in-
center HD,7 while offering better patient autonomy and
quality of life,8,9 at lower cost.10,11 PD remains the dominant
home dialysis therapy, comprising 15% of dialysis in
developed countries.12 In contrast, o2% of patients with
end-stage renal disease receive home HD.13 Yet, although the
use of PD has been steadily decreasing in developed
countries,12 the prevalence of home HD is increasing.13,14
Many advocate home HD in order to facilitate the delivery
of more intensive dialysis, delivered as more frequent (at least
5 days per week) and/or longer (at least 6 h per treatment)
sessions. However, whether such intensive HD therapies
improve hard outcomes over conventional three times per
week HD or PD is as yet unknown. Prior observational
studies suggested that home frequent HD was associated with
better survival than in-center three times per week HD.15–19
Despite rigorous methods used in some of these studies to
match groups on known prognostic variables,15–17 these
studies are difficult to interpret, as they compared home
patients with in-center patients. Compared with patients
receiving in-center HD, patients performing their own
treatments at home may have better health literacy, social
support, financial resources, cognitive function, and motiva-
tion. It is thus unclear whether the observed improvements in
survival in these studies were related to greater HD frequency
and duration, or to these other unmeasured factors. A recent
observational study comparing home intensive with home
CHD found no difference in survival between groups,20 and
the Frequent Hemodialysis Network Nocturnal Randomized
Trial surprisingly noted significantly increased mortality with
six nights per week home HD compared with three days per
week home HD.21
Nevertheless, the recent growth in home HD has likely
been facilitated by options for more frequent and/or longer
treatments, the possibility of night-time treatments, the recent
development of easier-to-use machines, and better funding
models.13,22 As home HD becomes more widely available,
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patients needing dialysis are now faced with a multitude of
choices: hospital or home-based therapy; if home-based, PD
or home HD; if HD, what frequency and duration? Few
comparative effectiveness studies of these options exist to help
guide these choices. Given that patients opting for home daily
HD often also have the choice of doing PD instead, studies
comparing the effects of these two therapies on clinically
important, patient-centered outcomes are highly relevant.
Acknowledging differences in technique, training time, and
available home care support between home daily HD and PD,
appropriately matched comparisons of home daily HD with
PD would have the added advantage of being less subject to
selection bias introduced by self-care ability, as both therapies
are performed at home. This may be particularly true of home
HD with newer devices that have improved the ease of
training for home daily HD.23
With these considerations, we performed an observa-
tional matched retrospective cohort study to compare
dialysis-related hospitalization risk associated with DHD
versus PD. We hypothesized that DHD would result in less
cardiovascular, infectious, and bleeding admissions, but
similar access-related hospitalizations compared with PD.
This hypothesis was based on the theoretical benefits of
DHD over PD, including higher daily ultrafiltration capacity,
greater small solute clearance with potentially improved
hemostasis and immune function, but an equal tendency
to vascular access or PD catheter–related complications.
Notwithstanding the limitations of home versus in-center
analyses discussed above, we also compared hospitalization
risk between home DHD and in-center three times per
week CHD to serve as a reference point in the context of
previous studies.
RESULTS
Study sample, baseline characteristics, and dialysis
prescription
Of 1386 potentially eligible DHD subjects, 1116 (81%) were
matched to 2784 PD controls, and 1187 (86%) were matched
to 3173 in-center CHD controls (Table 1). Distribution of
baseline variables was similar between DHD and comparator
groups with standardized differences of o10% for all variables
(Table 2). The mean treatment time received by DHD
subjects was 2.7 h (s.d.= 0.6, interquartile range= 2.4-2.9 h)
during month 1 and 2.9 h (s.d.= 0.6, interquartile range=
2.5–3.4 h) by 24 months (Figure 1). Eighty-nine percent of
DHD patients used low dialysate flow rates of 300 ml/min; the
remaining received ⩾ 900 ml/min. Mean percent reduction in
urea was 40% per treatment (s.d.= 10, interquartile range=
35–43). Of PD controls, 68% received continuous ambula-
tory PD, whereas 32% used a cycler.
DHD versus PD
There were 2443/3900 patients who had 8103 hospitalizations
during 6429 patient-years (mean follow-up 1.6 years,
s.d.= 1.3). The composite hospitalization rate was signifi-
cantly lower for DHD compared with PD (DHD: 0.94/
patient-year, PD: 1.36/patient-year; hazard ratio (HR)= 0.73
(95% confidence interval (CI)= 0.67–0.79); Po0.001).
Results were similar when we included only up to three
hospitalizations per patient, excluded recurrent hospitaliza-
tions occurring within 14 days of a previous one, and restricted
the analysis to the subgroup whose index date was o1 year
after start of end-stage renal disease. The subdistribution HR of
time to first hospitalization with DHD versus PD, accounting for
the competing events of death and transplantation, was similar
Table 1 |Patient flow
Home DHD Home PD Home DHD In-center CHD
No of patients aged⩾ 18 years 2501 195,465 2501 1,519,609
Exclusions
Not in the time windowa 0 133,908 0 109,623
Not Medicare before index 922 41,280 922 —
Nonindependent living 50 828 50 65,282
Missing race 0 1 0 573
Missing comorbidity 0 1 0 59
BMI450 or o16 or missing 87 634 87 116,201
Albumin o1.0 g/dl or hemoglobino5 g/dl 10 81 10 6057
Prior transplants42 2 5 2 30
Follow-upo30 days 44 618 44 41,537
Total no excluded 1115 177,356 1115 339,362
No eligible 1386 18,109 1386 1,180,247
No matched 1116 2784 1187 3173
Follow-up time (years) 1506 4923 1614 6885
(25/50/75th percentile) (0.6/1.2/2.0) (0.7/1.4/2.6) 0.6/1.2/2.0) (0.9/1.9/3.2)
Range 0.1–4.8 0.1–5.4 0.1–4.8 0.1–7.9
Abbreviations: BMI, body mass index; CHD, conventional hemodialysis; DHD, daily home hemodialysis; HD, home hemodialysis; No, number; PD, peritoneal dialysis; USRDS,
United States Renal Data System.
aThe time window was defined as having started renal replacement therapy after 1995, as end-stage renal disease patients were more completely captured in the USRDS
after this date. In addition, only patients who started PD between 2004 and 2009 were eligible to be selected as PD controls, as DHD subjects also began HD during this
period.
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to the primary analysis (HD= 0.64, (95% CI= 0.58–0.71);
Po0.001).
Patients receiving DHD spent a mean of 5.2 days per
patient-year in hospital, compared with PD patients
who spent 9.2 days per patient-year (Po0.001). Fifty-two
percent of DHD versus 32% of PD patients remained
admission-free (P=o0.001) during follow-up. Hospi-
talization rates owing to the prespecified individual causes
were each significantly lower with DHD than with PD
(Figure 2).
Table 2 |Baseline characteristics
Variable
Home DHD
n=1116
Home PD
n=2784
Standardized
difference
Home DHD
n=1187
In-center CHD
n=3173
Standardized
difference
Age (years) 50.5 (15.8) 50.9 (15.6) 2.1 50.3 (15.9) 50.8 (15.7) 2.9
18–29 years (%) 10.5 9.2 4.4 10.6 9.7 3.0
30–39 years (%) 18.2 16.2 5.3 19.2 19.0 0.4
40–49 years (%) 18.6 17.9 1.8 17.4 17.7 1.0
50–59 years (%) 19.4 20.8 3.5 20.3 20.1 0.5
60–69 years (%) 20.8 22.2 3.3 19.8 20.6 2.0
470 years (%) 12.6 13.9 3.7 12.8 12.8 0.2
Male sex (%) 67.3 66.9 0.9 67.6 67.6 0.1
Smoker (%) 7.4 6.9 1.9 7.2 7.3 0.6
BMI (kg/m2; %) 29.0 (6.8) 28.6 (6.2) 6.0 29.6 (7.2) 29.8 (7.1) 1.8
Race
White (%) 70.9 73.1 1.9 68.8 68.0 1.9
Black (%) 26.6 25.1 3.4 28.1 29.1 2.1
Others (%) 2.5 1.2 9.7 3.0 3.0 0.4
ESRD start date
1977–1994 (%) 0.6 0.6 0.4 0.6 0.4 3.5
1995–1999 (%) 8.1 7.6 1.6 8.3 6.7 6.1
2000–2004 (%) 21.2 22.1 2.0 23.0 22.5 1.2
2005–2009 (%) 70.1 69.8 0.6 68.0 70.4 5.1
ESRD duration (years) 3.3 (2.9) 3.3 (3.2) 2.3 3.5 (2.9) 3.5 (2.7) 0.7
1–3 months (%) 0.9 1.0 1.4 0.9 1.0 1.1
3–6 months (%) 7.4 8.4 4.0 7.5 8.4 3.4
6–12 months (%) 10.7 11.7 3.3 10.8 12.0 3.8
12–24 months (%) 18.0 19.6 4.0 18.5 20.3 4.8
24–48 months (%) 32.4 34.4 4.4 31.1 30.8 0.6
48–72 months (%) 15.9 13.9 5.5 15.1 14.3 2.4
72–96 months (%) 5.9 4.2 8.0 7.5 6.7 3.0
496 months (%) 8.9 6.8 8.2 8.6 6.4 8.3
Access type
AV fistula (%) 10.9 — — 10.6 9.4 3.9
AV graft (%) 2.1 — — 2.0 2.1 0.6
Catheter (%) 33.8 — — 34.9 33.4 3.1
Unknown (%) 53.2 — — 52.5 55.0 5.1
Wait-listed for transplant (%) 40.6 40.1 1.0 39.0 38.1 2.9
Prior transplant (%)
0 88.7 90.8 6.8 91.3 93.5 8.4
1 10.1 8.6 5.4 8.4 6.4 7.8
2 1.1 0.7 5.0 0.2 0.1 3.9
Comorbidities
Diabetes (%) 24.1 24.9 2.0 22.9 23.5 1.4
Hypertension (%) 82.0 82.2 0.3 82.1 81.6 1.3
CHF (%) 16.5 16.1 1.0 18.1 18.3 0.6
IHD (%) 6.3 7.4 4.6 5.5 5.8 1.5
CVD (%) 2.6 2.1 3.7 4.8 5.5 3.3
PVD (%) 7.8 8.4 2.1 8.3 9.5 4.4
COPD (%) 5.1 5.39 1.3 5.3 5.26 0.2
Cancer (%) 3.3 2.51 4.8 5.8 3.56 10.4
Lab values
Albumin (g/dl; %) 3.3 (0.71) 3.3 (0.71) 2.8 3.3 (0.7) 3.3 (0.7) 2.9
Hemoglobin (g/dl; %) 10.1 (1.77) 10.0 (1.77) 4.5 10.0 (1.8) 10.0 (1.8) 3.4
Abbreviations: AV, arteriovenous; BMI, body mass index; CHD, conventional hemodialysis; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVD,
cerebrovascular disease; DHD, daily hemodialysis; ESRD, end-stage renal disease; IHD, ischemic heart disease; PD, peritoneal dialysis; PVD, peripheral vascular disease.
Results are presented as mean (s.d.) or percentage as indicated.
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DHD versus in-center CHD
There were 2629/4360 patients who had 9065 hospitalizations
over 8299 patient-years (mean follow-up 1.9 years, s.d.= 1.4
years). There was no significant difference in the composite
hospitalization rate between home DHD and in-center CHD
(DHD: 0.93/patient-year, CHD: 1.10/patient-year; HR= 0.92
(95% CI= 0.85–1.00); P= 0.053).
Results were similar when we included only up to three
hospitalizations per patient, excluded recurrent hospitaliza-
tions occurring within 14 days of a previous one, and
restricted the analysis to the subgroup whose index date was
o1 year after the start of end-stage renal disease. The
subdistribution HR of time to first hospitalization with DHD
versus CHD, accounting for the competing events of death
and transplantation, was similar to the primary analysis
(HR= 0.90, (95% CI 0.71–1.19); P= 0.357).
Patients receiving home DHD spent fewer days in hospital
than patients receiving in-center CHD (5.2 vs. 7.0 days per
patient-year, respectively, P= 0.011). However, there was no
significant difference between groups in the proportion of
patients remaining admission-free during follow-up (DHD
51% vs. CHD 50%, P= 0.62). Cardiovascular hospitalizations
were significantly lower with DHD than with CHD (HR=
0.68 (95% CI= 0.61–0.77), Po0.001), whereas infectious
and access-related hospitalizations were significantly higher
(HR= 1.15 (95% CI= 1.04–1.29); P= 0.006, and HR= 1.25
(95% CI= 1.08–1.43); P= 0.002), respectively (Figure 3). Of
the latter, access infections appeared to account for the higher
observed HR (Figure 3).
Dialysis modality switches
Approximately 1% (9/1162) of DHD patients switched to PD,
whereas 25% (691/2784) of PD patients switched to home HD
(defined as ‘cross-overs’). During follow-up, 15% (172/1116) of
the DHD group compared with 44% (1233/2784) of the PD
group switched back to in-center CHD (defined as ‘modality
failure’). In both groups, 480% of the modality failures
occurred within the first year, whereas 490% occurred by
2 years. The hazard of switching back to in-center CHD with
PD relative to DHD was 3.4 (95% CI= 2.9–4.0, Po0.001).
DISCUSSION
Home dialysis offers patients independence, scheduling
flexibility, less time spent in dialysis facilities, and autonomy
to choose the dialysis modality they prefer. Most nephrolo-
gists feel that home dialysis is underutilized,24 and the
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importance of patient education in improving home dialysis
uptake is recognized.2,25–27 Home HD and PD are viewed as
complementary therapies, with modality choice predomi-
nantly determined by patient preference.1,2 Although PD
remains the dominant home therapy, the use of home HD is
increasing. How home HD compares in efficacy with PD on
patient-centered outcomes is unclear. We conducted this
study to address this knowledge gap.
In this retrospective cohort of predominantly prevalent
patients receiving in-center HD, we found that patients who
switched to home daily HD had a reduced risk of hospitaliza-
tion because of cardiovascular, infectious, access-related, and
bleeding causes, compared with those who switched to PD.
Compared with PD patients, daily HD patients spent 43%
fewer days in hospital owing to the prespecified causes, and
significantly more daily HD patients than PD patients
remained admission-free during follow-up. We also observed
that home daily HD was a significantly more sustainable
therapy than PD: ~ 15% of patients in the daily HD group went
back to in-center conventional HD by 2 years, compared with
almost 50% of PD patients during the same time period.
Previous studies comparing HD and PD have focused on
in-center conventional HD. In an analysis of United States
Renal Data System (USRDS) data, PD was associated with a
significantly increased risk of hospitalization after adjustment
for baseline factors (RR= 1.14, 95% CI= 1.13–1.15).28 This
association was confirmed by a prospective Canadian study,
with relative risks in the range of 1.10–1.26 in favor of HD.29
Two smaller, more recent prospective studies found no
significant differences in admission rates between groups.30,31
It is difficult to compare our results with these studies,
as we evaluated specific rather than all-cause hospitalizations.
Interestingly, Lafrance observed 52% more infectious hospi-
talizations in patients receiving PD than propensity score–
matched patients receiving in-center conventional HD;32 we
observed a 23% increase with PD compared with home DHD.
What possible mechanisms underlie our findings? All
patients received home DHD using a single manufacturer’s
device. DHD with this device typically uses lower dialysate
flow rates than conventional in-center HD (15–30 rather than
90–120 l per treatment), yet it still provides greater weekly
clearance than does PD (mean urea standard Kt/V 2.5 vs. 1.8
per week).33 Uremia has been linked to impaired immune
function.34,35 Whether more dialysis improves these para-
meters has never been shown, but if true could explain
the reduced risk of infection and access infection–related
admissions that we observed with DHD than with PD. As
DHD allows more ultrafiltration and phosphate removal than
PD,33 it is plausible that these factors contributed to reduced
cardiovascular admissions with DHD. Finally, the possibility
that PD patients were hospitalized more frequently because
they were more frail than home DHD patients despite
propensity-score matching cannot be excluded.36 However,
we did exclude patients living in institutions or in assisted-
living situations to reduce this likelihood.
The PD discontinuation rates that we observed are concern-
ing. Jaar et al.37 found PD discontinuation rates of 25% during
the first year of starting PD, whereas ours were more than
double that (55% during the first year). Even if we do not count
patients who crossed over from PD to DHD, as they still were
able to continue on a home therapy, the proportion of patients
who switched from PD to in-center HD was still higher than
those observed by Jaar et al.37 (37% during the first year). The
high PD discontinuation rates that we observed may be related
to the fact that ours was a prevalent rather than incident sample
—~80% of patients in our study had been on dialysis for 41
year. Prevalent patients are more likely to have lost residual renal
function, which is a significant predictor of PD failure.38
Alternatively, patients already established on in-center CHD
who switch to PD may have more barriers to PD than those who
start PD from the outset. Whether increased availability of home
HD would allow more PD patients who are failing PD to do
home HD rather than in-center HD is not known. Further study
is needed into the factors resulting in significantly poorer long-
term success of PD compared with home DHD.
Patients switching from in-center CHD to home DHD had
a similar risk of the composite outcome as patients continuing
in-center CHD, as a significant reduction in cardiovascular
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hospitalizations with DHD was offset by a concomitant
increase in admissions from infections (both general and
access-related). More frequent ultrafiltration likely affords
better control of euvolemia, potentially reducing cardiovascular
risk—a finding consistent with the Frequent Hemodialysis
Network Daily Trial, which showed significantly improved left
ventricular mass with six times versus three times per week
HD.39 However, why DHD patients had more infectious
admissions than CHD patients is puzzling. Any residual
confounding from comparing home with in-center patients
would have biased our results in the opposite direction,
suggesting that the observed association is in fact real. Our data
on treatment time and urea clearance confirm that DHD
patients received the prescribed therapy, reducing issues of
noncompliance. Perhaps DHD patients had increased bacterial
exposure owing to more frequent contact of the blood with
foreign materials (dialyzer, water, needles and so on) and more
frequent access cannulation, resulting in increased and/or more
severe infections requiring hospital admission. Home DHD
patients may also have had higher rates of buttonhole rather
than rope-ladder cannulation, a factor observed to cause
infection.40 Alternatively, this finding may simply be a conse-
quence of logistics: whereas patients receiving in-center CHD
have the opportunity to receive intravenous antibiotics during
their HD sessions when needed, patients dialyzing at home may
have required hospital admission to receive intravenous
antibiotics. Further study is needed to distinguish between
these possibilities. It should be mentioned that unlike the FHN
Daily Trial we did not find any increased risk of noninfection-
related access complications with more frequent HD. Finally, as
there is little difference in weekly urea clearance with DHD
using low dialysate flows and CHD,33 it is not surprising that
bleeding admissions were similar between these groups.
Our study is the first to address the comparative clinical
effectiveness of home DHD versus PD, and has several
methodological strengths. We analyzed data from a complete
data set of consecutive patients receiving DHD from a single
provider, eliminating the bias that arises from inclusion of
only prevalent long-term survivors. We obtained baseline
variables and outcomes data from a single well-validated data
source to avoid information bias. Our choice of the composite
outcome was hypothesis-based, and we used standard USRDS
definitions to classify hospitalizations. We used rigorous
methods to match patients on all known baseline character-
istics. Most importantly, the comparison of home DHD with
home PD not only addresses an important clinical question
but substantially reduces the risk of confounding owing to
factors often associated with the ability to dialyze at home.
We recognize the limitations of observational studies
using administrative data sets, the most important being that
analysis is limited to the data actually collected. Consequently,
we were unable to match on potentially important prognostic
variables, such as frailty index, help of an unpaid caregiver to
perform home dialysis, vascular access type (relevant for the
two HD comparisons), residual renal function, or the reasons
that DHD or PD were started, and were are thus unable to
completely exclude residual confounding or indication bias.
We were unable to match exactly on the index date. However,
given how closely the groups were matched at the start of
end-stage renal disease, there is no reason to believe that the
accumulation of comorbidities between the start of end-stage
renal disease (or match date) and the index date would differ
substantially between groups. Moreover, when we restricted
our analysis to the subgroup of patients whose index date was
o1 year after the start of end-stage renal disease, we obtained
similar HRs as for the main analysis, suggesting that our
results are robust. We do not have data on the mechanisms
underlying our observations, and we did not have any
information on the reasons for PD discontinuation. It is also
important to note that our results cannot be extrapolated to
frequent HD therapies using other DHD dialysis devices that
provide high dialysate flows. Finally, due to having to restrict
our cohort to patients with Medicare as their primary insurer,
ours was mostly a prevalent cohort with mean time on dialysis
of over 3 years; as such these results may not apply to incident
patients newly starting renal replacement therapy in whom
PD is often promoted as the initial dialysis modality.3,5,6
In summary, our study provides timely, highly relevant
information for prevalent patients considering home dialysis.
Our results suggest that in prevalent patients hospitalization
risk is equal between home DHD and in-center CHD, but that
PD is associated with higher risks of hospitalization and a
substantially greater risk of modality failure. Given the negative
impact of hospitalizations on cost-effectiveness and quality of
life, these results have implications for programs and patients.
Well-conducted prospective studies are needed to confirm
these findings, and to better determine whether the observed
associations are causal by identifying the underlying mechan-
isms. Future studies should also evaluate the reasons for the
higher rates of modality failure in prevalent patients choosing
PD versus those who choose DHD.
MATERIALS AND METHODS
Data sources
We identified patients receiving DHD, a large US dialysis provider’s
administrative database, which contains detailed information for all
patients receiving dialysis within its facilities. We selected control
patients receiving PD and in-center CHD from the USRDS. The
USRDS is an integrated national database that includes data on
demographics, diagnoses, biochemistry, dialysis claims, treatment
history, hospitalizations, and vital status for all patients with end-
stage renal disease in the US since 1995.41 We obtained detailed
dialysis prescription and treatment information for DHD patients
from the provider’s database. To avoid information bias, we obtained
all other data for all study cohorts (including baseline variables,
hospitalizations, modality switches, and deaths) from the USRDS.
The provider supplied the data and allowed linkage to USRDS for a
fee; the company had no input into the study design or analyses. All
analyses adhered to a detailed, predefined protocol, and we prepared
this manuscript according to STROBE guidelines.30
Study sample
We included all adults ⩾ 18 years old who began DHD (45 days/
week, 1.5–4.5 h/day) between January 2004 and December 2009 in
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the provider’s facilities. All DHD patients used a single dialysis
device;33490% received DHD using low dialysate flows (o300ml/
min). We selected two comparator groups of adults ⩾ 18 years old
receiving PD and CHD from USRDS from the same time period. As
complete hospitalization data are only available from USRDS for
patients who are insured by Medicare as primary payor, we excluded
patients from both groups who did not meet this criteria. We also
excluded DHD patients who received PD, and PD controls who
received DHD at any time. To avoid elimination of potentially
‘healthier’ patients from the CHD group, CHD controls who
received PD first were not excluded (114/3173; 3.6% of the final
cohort). Other exclusions are listed in Table 1.
Primary outcome, index date, and follow-up
The primary outcome was the composite of all hospitalizations from
the index date to the end of follow-up owing to the prespecified
causes of cardiovascular, infectious, access-related, and bleeding.
Study variables
All diagnoses were classified as in the USRDS 2012 Annual
Report using the ICD-9/10 systems.41 We defined the index date
as DHD or PD start date, and then matched DHD and PD patients
by duration of end-stage renal disease (vintage) before this date to
avoid immortal time bias.42 Because CHD controls did not have a
‘natural’ index date, the index date was calculated as dialysis
start date plus the matched DHD’s subject’s vintage; only patients
who were alive and receiving CHD on the index date were thus
eligible to serve as controls. To reduce bias from informative
censoring for patients who discontinued DHD or PD, we attributed
all events occurring up to 90 days after dialysis modality switches to
the prior modality.
Statistical analysis
Derivation of propensity scores. We constructed a logistic
regression model to predict the receipt of DHD versus PD using the
following covariates available at the start of end-stage renal disease:
age, sex, race, body mass index, diabetes, hypertension, congestive
heart failure, cerebrovascular disease, peripheral vascular disease,
chronic obstructive pulmonary disease, cancer, prior transplant,
medical insurance coverage, albumin, and hemoglobin. From this
model, we calculated a propensity score for each patient, which is the
estimated probability of being assigned DHD over PD given the
observed covariates in our logistic regression model.43 Because DHD
and PD patients with the same propensity score will have similar
distributions of observed baseline covariates, matching on propensity
score reduces the impact of selection bias.44,45 We used a similar
approach to calculate the propensity score of receiving DHD
versus CHD.
Matching procedures. Using the ‘greedy match’ macro,46 we
matched between one and three PD patients to each DHD patient by
the following: the propensity score (caliper width= 0.02), first renal
replacement therapy start date (5-year intervals from 1995 to 2009),
duration of end-stage renal disease before index date (index date minus
first renal replacement therapy start date: 1–3 months, 3–6 months,
6–12 months, 12–24 months, 24–48 months, 48–72 months,
72–96 months, 496 months), age (3-year intervals), sex, race, body
mass index (5 kg/m2 intervals), congestive heart failure, cancer, and
cerebrovascular disease. We evaluated various caliper widths for the
propensity score iteratively, and chose the width that produced
the most matches while maintaining between-group standardized
differences of o10%. Matching on first renal replacement therapy
start date and vintage were prespecified to control for era effects and
survivor bias, whereas the other variables were added later owing to
variable imbalance after propensity-score matching.47,48
Similarly, we matched 1–3 CHD patients to each DHD patient by
propensity score (caliper width= 0.02), first renal replacement
therapy start date, age (3-year intervals), sex, race, body mass index
(5 kg/m2 bins), albumin (1.5 g/dl intervals), congestive heart failure,
diabetes, and prior transplant. Duration of end-stage renal disease
was matched by definition, given the method by which we calculated
the index date for CHD patients (see above).
Baseline characteristics. We reported standardized differences
in baseline characteristics between daily and conventional groups;
differences410% were considered important.49,50 When estimating
descriptive statistics and standardized differences, each control
patient was weighted by the inverse of the number of control
patients within the matched set.51
Primary outcome. We used an Andersen–Gill model,52
accounting for matched strata, to evaluate time to all hospitalizations
owing to the prespecified causes, and to estimate the relative change
in the hazard of hospitalization owing to DHD compared with PD,
and owing to DHD compared with CHD. A robust sandwich
covariance matrix structure was used to account for intra-individual
correlation between repeated events for the same individual. Events
of transplantation, death, recovery of renal function, and loss to
follow-up were censored; switches from DHD or PD to an alternative
dialysis modality were censored at 90 days after the switch to reduce
bias from informative censoring.
Sensitivity analyses. To ensure that a small group of patients
with multiple readmissions were not primarily responsible for
the observed results, we repeated the primary analysis excluding
hospitalizations after the 3rd, and any occurring within 14 days of a
previous one. Given that patients may have accumulated comor-
bidities between start of end-stage renal disease when matching
variables were available and the index date, we repeated the primary
analysis in the subgroup of patients whose index date was o1 year
from the start of end-stage renal disease. Finally, recognizing the
potential for informative censoring due to the competing events of
death and transplantation, we performed a competing risk analysis
for time to first hospitalization owing to the prespecified causes using
the approach of Fine for stratified data.53,54
Secondary outcomes. We used the approach described
above for individual components of the composite outcome. We
compared the number of days spent in the hospital between
groups using a negative binomial regression with generalized
estimating equation to account for the correlation within
each matched strata.55 We compared the proportion of patients
remaining admission-free during follow-up using conditional logistic
regression.
We compared modality failure (defined as switch to in-center
conventional HD) for home DHD and PD using the stratified
two-sided log-rank test.56 Events of death, transplantation, and loss
to follow-up were censored. PD outcomes were weighted by the
inverse of the number of PD patients per matched set. We used a
Cox proportional hazards model, stratified by matched sets, to
estimate the relative change in the hazard of modality failure owing
to DHD compared with PD.
All HRs are presented as unadjusted. We performed all analyses
using SAS 9.2 (Cary, NC), except for the stratified competing risk
analysis, which was performed in R (3.0.2, R foundation for
366 Kidney International (2015) 88, 360–368
c l in i ca l inves t iga t ion RS Suri et al.: Hospitalization with daily hemodialysis
statistical computing). We used two-sided P-values and considered
Po0.05 statistically significant.
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